C2N Diagnostics announced it has received a $15 million program-related investment from GHR Foundation to support development of a blood test targeting tau tangle pathology in Alzheimer’s disease. According to the company, the test aims to help diagnose and stage the disease by detecting tau proteins that form tangles in the brain.
The company said the funding will accelerate research and clinical validation of its tau assay as part of its broader pipeline of blood-based diagnostics. C2N Diagnostics claims the test could complement its Precivity blood test, which currently measures amyloid beta to support Alzheimer’s diagnosis.
C2N Diagnostics also said the investment will help expand testing capabilities and explore integration of tau and amyloid biomarkers for more comprehensive disease assessment. The company claims its approach could provide clinicians with accessible tools to detect and monitor Alzheimer’s earlier and more accurately.
According to the company, the tau tangle test is intended to address an unmet need in Alzheimer’s care by offering non-invasive detection of neurofibrillary tangles, which are a hallmark of disease progression. C2N Diagnostics claims the development aligns with its mission to advance precision medicine solutions for neurodegenerative diseases.
